GSK to Buy Cancer Drugmaker Nuvalent for $10.6 Billion

GSK is buying Nuvalent for $10.6 billion, a significant bet on targeted cancer therapies, STAT News reports. The acquisition gives GSK control of Nuvalent's late-stage lung cancer candidates, including zidesamtinib and neladalkib, which are designed to hit specific genetic drivers of disease while limiting the side effects that plague older treatments.

The move fits a clear industry pattern. Large drugmakers facing patent expirations on blockbuster products are spending heavily to acquire promising clinical-stage assets rather than build them in-house. Targeted oncology has become a favored hunting ground because precision drugs can command premium pricing and serve patient populations defined by molecular testing.

For GSK, the deal deepens an oncology portfolio it has worked to rebuild after earlier divestitures. For the broader market, it signals continued appetite for sizable, pipeline-focused acquisitions. Investors should watch how regulators view the price and how quickly GSK can advance Nuvalent's candidates toward approval, where commercial returns ultimately hinge on trial outcomes.